Pfizer Reports real-world evidence Data for Glofitamab in Crohn's disease

Pfizer today announced real-world evidence results for glofitamab in patients with Crohn's disease. The study demonstrated that glofitamab reduces exacerbation rates compared to standard of care or placebo. These results provide important insights into the treatment of Crohn's disease and support the continued development of glofitamab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.